BioAge Labs 2026年季度报告

OR BIOAGE LABS, INC. Delaware(State or other jurisdiction ofincorporation or organization)5885 Hollis St, Suite 370Emeryville, CA(Address of principal executive offices) Securities registered pursuant to Section 12(b) of the Act: Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities ExchangeAct of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has beensubject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant toRule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required tosubmit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reportingcompany, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and“emerging growth company” in Rule 12b-2 of the Exchange Act. Accelerated filer☐Smaller reporting company☒ Large accelerated filer☐Non-accelerated filer☒Emerging growth company☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complyingwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒As of July 31, 2026, the registrant had 45,896,909 shares of common stock, $0.00001 par value per share, outstanding. Table of Contents PART I.FINANCIAL INFORMATION Item 1.Financial Statements (Unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’ EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and Procedures PART II.OTHER INFORMATION Item 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignatures SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q (this Quarterly Report) contains forward-looking statements. All statements other thanstatements of historical facts contained in this Quarterly Report are forward-looking statements. In some cases, you can identifyforward-looking statements by terms such as “aim,” “may,” “will,” “should,” “expect,” “forecast,” “plan,” “anticipate,” “could,”“intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these termsor other similar expressions, although not all forward-looking statements contain these words. All statements other than statementsof historical fact contained in this Quarterly Report, including without limitation statements regarding our plans to develop andcommercialize our product candidates, including BGE-102 and our APJ programs, the potential for BGE-102 as a treatment fordiseases driven by inflammation including retinal diseases such as diabetic macular edema and the expected timeline for datareadouts from our ongoing Phase 2 dose-ranging clinical trial, the timing and results of our ongoing or planned preclinical studiesand clinical trials, risks associated with clinical trials, including our ability to adequately manage clinical activities, the timing ofIND filings for our APJ programs, unexpected concerns that may arise from additional data or analysis obtained during clinicaltrials, the timing of and our ability to obtain and maintain regulatory approvals, the clinical utility of our product candidates, ourcommercialization, marketing and manufacturing capabilities and strategy, our expectations about the willingness of healthcareprofessionals to use our product candidates, the sufficiency of our cash, cash equivalents, and marketable securities, generaleconomic, industry and market conditions, including fluctuating interest rates and inflation, cybersecurity incidents, significantpolitical, trade or regulatory developments, including tariffs, any future federal government shutdowns, or shifting priorities withinthe U.S. Food and Drug Administration, and political instability and military hostilities in multiple geographies, such as the conflictsin Ukraine, Venezuela, Iran, tensions between China and Taiwan and the possibility of a wi